Alerta

SubA mutant and application thereof in construction of endoplasmic reticulum stress state cell model

Resumen de: CN120271678A

The invention provides a SubA mutant and application thereof in construction of an endoplasmic reticulum stress state biological model, and particularly provides application of polypeptide in preparation of the biological model, the biological model is in an endoplasmic reticulum stress state, and compared with SEQ ID NO: 3, the polypeptide has p.Ser272Ala mutation. It is found that when Ser272 residues in SubA are mutated into Ala residues, a protein only having degenerative enzyme activity can be generated, cell death cannot be caused, meanwhile, a Tet-on system is added to regulate and control efficient expression of SubA272, and therefore a tumor biological model in an endoplasmic reticulum stress state can be efficiently prepared; a research tool is provided for mechanism research of endoplasmic reticulum stress and tumor occurrence and proliferation and tumor treatment.

Application of serum marker for intestinal mucosa inflammation

Resumen de: CN120254281A

The invention relates to application of an intestinal mucosa inflammation serum marker in preparation of a diagnosis and treatment product for treating the intestinal mucosa inflammation state of a patient suffering from Crohn disease and predicting the treatment effect of infliximab, and belongs to the technical field of biological medicine, and the intestinal mucosa inflammation serum marker is matrix remodeling related 5 protein (MXRA5). When the matrix remodeling related 5 protein (MXRA5) is used as a target spot for serum protein detection, high sensitivity and specificity are achieved, and therefore the MXRA5 protein can be used as a screening target spot for predicting the intestinal mucosa inflammation state of a patient suffering from the Crohn disease and the treatment effect of the infliximab.

Application of detection reagent of interleukin-22 in preparation of product for predicting radioactive intestinal injury sensitivity

Resumen de: CN120249470A

The invention discloses application of a detection reagent of interleukin-22 in preparation of a product for predicting radioactive intestinal injury sensitivity, and belongs to the technical field of medical detection. The expression level of IL-22 before radiation is related to the severity of intestinal injury after radiation, mice with high expression of IL-22 show more serious intestinal injury symptoms after radiation, IL-22 can be used as a biomarker for predicting sensitivity of radioactive intestinal injury, the risk of intestinal injury can be preliminarily evaluated by detecting the level of IL-22 before individual radiation, and the risk of intestinal injury can be further evaluated by detecting the level of IL-22 before individual radiation. Early warning is realized; the IL-22 can increase the radiosensitivity of intestinal tissues, the kit provided by the invention adopts a modern detection technology, such as enzyme-linked immunosorbent assay (ELISA), performs high-sensitivity and high-specificity detection on the IL-22, is simple and convenient to operate, and supports multiple sample types. The kit has important scientific research value and application prospect, and is expected to play a key role in prevention and treatment of radioactive intestinal injury along with the development of nuclear energy technology and radiotherapy.

Marker combination for predicting recurrence of ulcerative colitis and application

Resumen de: CN120254292A

The invention provides a marker combination for predicting recurrence of ulcerative colitis and application thereof, and particularly, the marker is at least one of SLC6A14, MUC-2 and Nanncy index. The marker can be used for diagnosis and recurrence prediction of ulcerative colitis, and especially has relatively strong detection capability for relieving and recurrence conditions of patients after clinical drug treatment.

Application of membrane protein CMTM3 as drug target for treating inflammatory bowel disease and related colorectal cancer

Resumen de: CN120249471A

The invention relates to the field of biological medicine, and particularly provides application of a membrane protein CMTM3 as a drug target for treating inflammatory bowel disease and related colorectal cancer. The invention discovers and verifies that deletion of Cmtm3 can protect mice from AOM/DSS induced colorectal cancer (CAC) for the first time. A further research result proves that the endothelial cell-derived CMTM3 promotes the development of enteritis. The Cmtm3 gene knockout and the imatinimex can regulate the vascular permeability in a targeted manner and have a considerable curative effect. The application also discloses that the CMTM3 promotes vascular permeability to aggravate enteritis by stabilizing CLTC and increasing gridding protein mediated endocytosis of VE-cadherin in endothelial cells, thereby promoting the development of inflammation-related colon cancer, which indicates that the CMTM3 can be used as a potential therapeutic target for enteritis and colon cancer (CAC).

Quality control method and application of alhagi sparsifolia effective component for treating ulcerative colitis

Resumen de: CN120254102A

The invention provides a quality control method of an effective component of alhagi sparsifolia for treating ulcerative colitis and application of the quality control method, and the method comprises the following steps: characterizing the material composition of the effective component of alhagi sparsifolia by using an ultra-high performance liquid chromatography-mass spectrometry technology, and determining key active components by combining network pharmacology prediction and topological analysis; the quality internal control method for the effective components of the alhagi sparsifolia for treating the ulcerative colitis is constructed by adopting a high performance liquid chromatography technology and a thin-layer chromatography technology, the material information of the effective components of the alhagi sparsifolia can be comprehensively reflected, the quality of the effective components of the alhagi sparsifolia in different batches can be effectively monitored, and the method is high in precision, good in reproducibility and suitable for industrial production. The method can be used for controlling the quality of the effective components of the alhagi sparsifolia for treating ulcerative colitis, and provides a basis for solving the problem that the existing standard cannot comprehensively and systematically analyze the material composition and content control of the effective components of the alhagi sparsifolia.

CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT

Resumen de: US2025213709A1

The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.

AUTOMATED INFLAMMATORY BOWEL DISEASE DETECTION USING BOWEL SOUNDS MONITORED BY A WEARABLE SYSTEM

Resumen de: WO2025141157A1

The invention relates to a method for assisting the diagnosis of a bowel disease comprising the steps of: a) providing an audio-recording of sounds emitted by the bowel of a subject for the duration of at least one classification time window, b) analyzing the processed audio data thereby classifying at least a fraction of the recorded sounds as bowel sound, c) computing at least one Mel Frequency Cepstral Coefficient (MFCC)-feature from at least a fraction of the recorded bowel sounds extracted in b), d) determining at least one statistical parameter, preferably the mean and/or variance, of at least a fraction of the Mel Frequency Cepstral Coefficient (MFCC)-features computed in c) within at least one classification time window, e) using an artificial intelligence (AI) to classify the at least one classification time window as either being indicative for the individual suffering from a bowel disease or for a healthy individual, wherein the AI is taking into account the in step d) determined at least one statistical parameter of at least a fraction of the MFCC- features, thereby predicting the likelihood of a bowel disease for the subject. The invention further relates to the use of the present method for the diagnosis of a bowel disease, to a computer-implemented method and a software or computer program for predicting the likelihood of a bowel disease in a subject.

METHOD, PROGRAM, AND APPARATUS FOR DETECTING SMALL INTESTINAL BACTERIAL OVERGROWTH

Resumen de: AU2023327783A1

Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.

AUTOMATED INFLAMMATORY BOWEL DISEASE DETECTION USING BOWEL SOUNDS MONITORED BY A WEARABLE SYSTEM

Resumen de: EP4578401A1

The invention relates to a method for assisting the diagnosis of a bowel disease comprising the steps of: a) providing an audio-recording of sounds emitted by the bowel of a subject for the duration of at least one classification time window, b) analyzing the processed audio data thereby classifying at least a fraction of the recorded sounds as bowel sound, c) computing at least one Mel Frequency Cepstral Coefficient (MFCC)-feature from at least a fraction of the recorded bowel sounds extracted in b), d) determining at least one statistical parameter, preferably the mean and/or variance, of at least a fraction of the Mel Frequency Cepstral Coefficient (MFCC)-features computed in c) within at least one classification time window, e) using an artificial intelligence (Al) to classify the at least one classification time window as either being indicative for the individual suffering from a bowel disease or for a healthy individual, wherein the Al is taking into account the in step d) determined at least one statistical parameter of at least a fraction of the MFCC-features, thereby predicting the likelihood of a bowel disease for the subject. The invention further relates to the use of the present method for the diagnosis of a bowel disease, to a computer-implemented method and a software or computer program for predicting the likelihood of a bowel disease in a subject.

マクロファージ刺激１受容体（ＭＳＴ１Ｒ）バリアント及びその使用

Nº publicación: JP2025098004A 01/07/2025

Solicitante:

リジェネロン・ファーマシューティカルズ・インコーポレイテッド

Resumen de: US2024075102A1

Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein.